LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

Search

Biogen Inc

Deschisă

SectorSănătate

137.98 0.41

Rezumat

Modificarea prețului

24h

Curent

Minim

135.28

Maxim

137.65

Indicatori cheie

By Trading Economics

Venit

394M

635M

Vânzări

215M

2.6B

P/E

Medie Sector

13.46

35.69

EPS

3.02

Marjă de profit

23.995

Angajați

7,605

EBITDA

457M

1B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+21.72% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.9B

21B

Deschiderea anterioară

137.57

Închiderea anterioară

137.98

Sentimentul știrilor

By Acuity

50%

50%

131 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Biogen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 sept. 2025, 18:25 UTC

Principalele dinamici ale pieței

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28 sept. 2025, 23:48 UTC

Market Talk

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28 sept. 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28 sept. 2025, 23:45 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28 sept. 2025, 23:34 UTC

Market Talk

Oil Falls on Likely Technical Correction -- Market Talk

27 sept. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 sept. 2025, 21:56 UTC

Achiziții, Fuziuni, Preluări

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 sept. 2025, 20:54 UTC

Câștiguri

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 sept. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 sept. 2025, 20:27 UTC

Achiziții, Fuziuni, Preluări

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 sept. 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 sept. 2025, 19:53 UTC

Achiziții, Fuziuni, Preluări

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept. 2025, 19:40 UTC

Câștiguri

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 sept. 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 sept. 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 sept. 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 sept. 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26 sept. 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 sept. 2025, 18:50 UTC

Market Talk
Câștiguri

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 sept. 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26 sept. 2025, 18:02 UTC

Achiziții, Fuziuni, Preluări

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 sept. 2025, 18:02 UTC

Achiziții, Fuziuni, Preluări

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 sept. 2025, 18:02 UTC

Achiziții, Fuziuni, Preluări

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 sept. 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 sept. 2025, 16:56 UTC

Market Talk
Câștiguri

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 sept. 2025, 16:41 UTC

Market Talk
Câștiguri

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 sept. 2025, 16:26 UTC

Câștiguri

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Biogen Inc Așteptări

Obiectiv de preț

By TipRanks

21.72% sus

Prognoză pe 12 luni

Medie 167.2 USD  21.72%

Maxim 224 USD

Minim 118 USD

În baza a 26 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBiogen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

26 ratings

12

Cumpărare

14

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

118.15 / 121.17Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

131 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat